Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy

Inclusion Criteria: * Participate voluntarily and sign informed consent; * Age ≥18 years old and ≤80 years old, regardless of gender; * Physical condition ECOG 0 \~ 2; * The diagnosis of pancreatic adenocarcinoma was confirmed by pathology; * Peritoneal metastasis was confirmed by ascites cytology, or was pathologically confirmed by surgical exploration and biopsy; * Expected survival ≥3 months; * No serious abnormal blood system, heart and lung function and immune deficiency (refer to respective standards); * Blood routine indicators: white blood cell (WBC) ≥3 × 109/L;Absolute count of neutrophils (ANC) ≥1.5 × 109/L;Platelet (PLT) ≥100 × 109/L;Hemoglobin (Hgb) ≥9 g/dL; * Blood biochemical indexes: AST (SGOT) and ALT (SGPT) ≤2.5 × upper limit of normal value (ULN);Total bilirubin (TBIL) ≤ULN;Serum creatinine (CRE) ≤1.5 × ULN; * Coagulation function: Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN; * Comply with the study visit plan and other program requirements. Exclusion Criteria: * Accompanied by other systemic malignant tumors; * Received any form of anti-tumor therapy, including interventional chemoembolization, ablation, radiotherapy, chemotherapy, tumor palliative resection and molecular targeted therapy; * Used any other study drugs within 5 weeks before enrollment; * Central nervous system diseases, mental diseases, unstable angina pectoris, congestive heart failure, severe arrhythmia and other serious diseases that cannot be controlled; * Uncontrolled infection, bleeding, pancreatic leakage, bile leakage, or other postoperative complications during baseline examination;Acute and chronic metabolic acidosis (including ketoacidosis and lactic acidosis) has not been corrected. * A history of allergy to study drugs or similar structured drugs; * Pregnant or lactating women; * Any conditions, including serious medical risk factors, medical conditions, and laboratory abnormalities, that may impair patient safety or the integrity of research data; * Intestinal obstruction, extensive adhesion in the peritoneal cavity, abdominal inflammation, etc.